2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-139125
    DCHC 302953-06-6 98%
    DCHC is a SIRT1 activator but does not induce SIRT1 expression. DCHC can be used for mitochondrial damage related studies.
    DCHC
  • HY-139174
    (S)-DO271 2301865-01-8 98%
    (S)-DO271 is a non-active control probe targeting ABHD12, and it has almost no inhibitory activity against ABHD12 (IC50 > 100 μM). (S)-DO271 does not cause the upregulation of inflammatory factors and has no cytotoxicity. (S)-DO271 is suitable as a negative control for validating the functional studies of ABHD12.
    (S)-DO271
  • HY-139184
    CCR5 antagonist 4 872879-86-2 98%
    CCR5 antagonist 4 is an orally active CCR5 antagonist. CCR5 antagonist 4 can be studied in research on rheumatoid arthritis.
    CCR5 antagonist 4
  • HY-139207
    Glucosamine sulfate potassium chloride 1296149-08-0 98%
    Glucosamine sulfate potassium chloride is an amino sugar and a prominent precursor in the biochemical synthesis of glycosylated proteins and lipids, is used as a dietary supplement. Glucosamine sulfate potassium chloride also is a natural constituent of glycosaminoglycans in the cartilage matrix and synovial fluid, which when administered exogenously, exerts pharmacological effects on osteoarthritic cartilage and chondrocytes.
    Glucosamine sulfate potassium chloride
  • HY-139247
    pNPS-DHA 2454246-25-2 98%
    pNPS-DHA (Compound 19) is an orally active DHA-ethanolamide (DHEA) derivative that has antiallergic activity. pNPS-DHA inhibits IgE-dependent passive cutaneous anaphylaxis (PCA) reaction in mice. pNPS-DHA has anti-degranulating activity in RBL-2H3 mast cells with an IC50 of 15 μM.
    pNPS-DHA
  • HY-139352
    Betamethasone 21-valerate 2240-28-0 98.0%
    Betamethasone 21-valerate is a corticosteroid ester with anti-inflammatory activities.
    Betamethasone 21-valerate
  • HY-139430
    4-Isopropylcatechol 2138-43-4 98.03%
    4-Isopropylcatechol is a potent and irreversible cutaneous depigmenting agent. 4-Isopropylcatechol significantly inhibits protein biosynthesis in mouse melanoma cells containing high levels of tyrosinase. 4-Isopropylcatechol can be use to study hyperpigmentation of skins.
    4-Isopropylcatechol
  • HY-139555
    Zectivimod 1623066-63-6 99.35%
    Zectivimod is a sphingosine-1-phosphate receptor agonist. Zectivimod can be used for the research of autoimmune diseases，chronic inflammatory diseases and immunoregulation disorders.
    Zectivimod
  • HY-13956A
    (R)-Pioglitazone-d1 1259828-75-5 98%
    (R)-Pioglitazone-d1 ((R)-U 72107-d1) is a stabilized and deuterated R-enantiomer of pioglitazone, exhibiting pharmacological properties that are beneficial for NASH treatment, including modulation of mitochondrial function, non-steroidal anti-inflammatory effects, and glucose-lowering capabilities.
    (R)-Pioglitazone-d1
  • HY-139594
    Polyketide synthase 13-IN-1 2345638-96-0 98%
    Polyketide synthase 13-IN-1 (compound 32) is a polyketide synthase 13 inhibitor.
    Polyketide synthase 13-IN-1
  • HY-139595
    Polyketide synthase 13-IN-2 2219338-48-2 98%
    Polyketide synthase 13-IN-2 (comp 42) is a polyketide synthase 13 inhibitor against Mycobacterium tuberculosis, with an MIC of 0.25 μg/mL.
    Polyketide synthase 13-IN-2
  • HY-139596
    Polyketide synthase 13-IN-3 2221801-50-7 98%
    Polyketide synthase 13-IN-3 (compound 41) is a polyketide synthase 13 inhibitor，with a MIC of 0.0625-0.125 μg/mL against the M. tuberculosis strain H37Rv.
    Polyketide synthase 13-IN-3
  • HY-139627
    P2X receptor-1 3051864-35-5 98%
    P2X receptor-1 is a potential inhibitor of P2X receptor for the research of pain and inflammation.
    P2X receptor-1
  • HY-139709
    Glucocorticoids receptor agonist 1 694526-54-0 98%
    Glucocorticoids receptor agonist 1 is a potent anti-inflammatory, arylpyrazole-based glucocorticoid receptor agonist that does not impair insulin secretion.
    Glucocorticoids receptor agonist 1
  • HY-139710
    Glucocorticoids receptor agonist 2 614761-20-5 98%
    Glucocorticoids receptor agonist 2 is a potent anti-inflammatory, arylpyrazole-based glucocorticoid receptor agonist that does not impair insulin secretion.
    Glucocorticoids receptor agonist 2
  • HY-139716
    IMD-catechol 2928463-39-0 98%
    IMD-catechol is a novel imidazoquinolinone-NF-κB immunomodulator dimer that improves efficacy in a CT26 mouse colon carcinoma tumor model while eliciting minimal adjuvant toxicity.
    IMD-catechol
  • HY-139718
    IMD-biphenylB 2928463-41-4 98%
    IMD-biphenylB is a potent imidazoquinolinone-NF-κB immunomodulator dimer that inhibits tumor proliferation while induces low systemic inflammation and reduces adjuvant toxicity.
    IMD-biphenylB
  • HY-139719
    IMD-biphenylC 2928463-42-5 98%
    IMD-biphenylC is a novel imidazoquinolinone-NF-κB immunomodulator dimer that inhibits tumor proliferation while induces low systemic inflammation and reduces adjuvant toxicity.
    IMD-biphenylC
  • HY-139757
    Antibacterial agent 40 1817768-97-0 98%
    Antibacterial agent 40 is an antibacterial agent (extracted from patent WO2015159265A1, compound C) .
    Antibacterial agent 40
  • HY-139758
    Antibacterial agent 41 1426572-45-3 98%
    Antibacterial agent 41 (example 3) is a antibacterial agent (extracted from patent WO2013030735A1).
    Antibacterial agent 41
Cat. No. Product Name / Synonyms Application Reactivity